In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Matinas BioPharma (MTNB – Research Report), with a price target of $1.00. The company’s shares closed last Friday at $0.22.
Harrison covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Viridian Therapeutics, and CymaBay Therapeutics. According to TipRanks, Harrison has an average return of 14.5% and a 54.03% success rate on recommended stocks.
Matinas BioPharma has an analyst consensus of Moderate Buy, with a price target consensus of $0.65.
See Insiders’ Hot Stocks on TipRanks >>
MTNB market cap is currently $46.97M and has a P/E ratio of -2.21.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Matinas BioPharma (MTNB) Company Description:
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company’s proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.
Read More on MTNB:
- Matinas announces results from two LNC-formulated oligonucleotides studies
- Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides
- Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
- Matinas BioPharma provides update to MAT2203 regulatory, development pathway
- Biotech Alert: Searches spiking for these stocks today
